Skip to Main Content


Skip Nav Destination


In This Issue

In the Spotlight

In Focus

Research Briefs

This subgroup analysis of patients with HER2-positive breast cancer with a history of brain metastases from DESTINY-Breast01 demonstrated the strong clinical activity of trastuzumab deruxtecan (T-DXd) in this patient population, warranting continued investigation.

In DNMT3A-mutant clonal hematopoiesis, the selective advantage of mutant hematopoietic stem cells is potentiated by TNFα–TNFR1 signaling, whereas TNFα–TNFR2 signaling specifies the lineage(s) of mature mutant blood cell types produced.

Research Articles

Remodeling of pancreatic ductal adenocarcinoma tumor–stroma interactions by FAK inhibition allows radiation therapy to prime antitumor immunity and unlock responsiveness to immunotherapy.

Serial circulating tumor DNA profiling in patients with neuroblastoma identifies dynamic tumor evolution, disease progression, and functionally relevant variants beyond that of standard clinical surveillance and direct tumor sequencing practices.

Single-cell transcriptomics of multifocal glioblastomas characterized properties of natural tumor evolution, as well as tumor migration and immunoenvironment remodeling.

Integrative 3D genomic analysis reveals that many germline risk alleles and somatic driver mutations dysregulate transcription in prostate cancer via enhancer reprogramming and long-range chromatin interactions.

Cutaneous, acral, and mucosal melanomas have alterations in components of MAPK, PI3K, p53, p16, and telomere pathways but different mechanisms of activation or inactivation, whereas uveal melanomas are genomically distinct.

The BAF complex, in particular ATPase subunit SMARCA4/BRG1, is critical for maintaining pediatric H3K27M-glioma cells in an oncogenic progenitor state, and pharmacologic inhibition is a potential therapeutic avenue for these highly aggressive tumors.

SMARCA4, the catalytic subunit of mammalian SWI/SNF complex, is critical for H3K27-Maltered diffuse midline glioma cells as well as regulates their gene expression and fitness, which suggests SMARCA4 as a potential therapeutic approach for this lethal disease.

In vivo CRISPR screening identified loss of epigenetic regulation as a critical tumorsuppressive mechanism that leads to basal mammary epithelial cell lineage infidelity, aberrant alveolar differentiation, and the acceleration of luminal breast tumor initiation.

News in Brief

News in Depth

Research Watch

Intratumoral Heterogeneity
Clinical Trial
Predictive Modeling
Tumor Microenvironment
Immune Evasion
Drug Evaluation
Drug Discovery
Extrachromosomal DNA


Close Modal

or Create an Account

Close Modal
Close Modal